Because of the monogenic aetiology of APS‐1, we hypothesised that the thymic compartment can be targeted to modulate immune tolerance by using a gene therapy approach to restore a functional copy of the AIRE gene. The gene discussed is AIRE; the disease is autoimmune polyendocrine syndrome type 1.